Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release

World News: . []

SEATTLE, April 16, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the presentation of new data for APVO436, a bispecific antibody candidate targeting CD123 and CD3, at the American Association for Cancer Research (AACR) 2018 Annual Meeting. The preclinical data demonstrate potent T-cell cytotoxicity of tumors expressing CD123 with limited cytokine release and suggest that APVO436 has the potential for increased clinical benefit and a favorable safety profile.   

Cytokine release syndrome (CRS) is a significant concern with T-cell activating therapies and has been associated with severe complications in clinical trials.  Aptevo has previously published data on its first generation candidate, APVO414, showing reduced cytokine release upon T-cell engagement compared to another bispecific format (). 

New preclinical data presented at this year’s AACR Annual Meeting compare Aptevo’s second generation bispecific, APVO436, with an Aptevo-generated version of Macrogenics’ CD123 x CD3 dual-affinity re-targeting (DART) molecule, MGD006, evaluating T-cell activation, proliferation, cytotoxicity and cytokine secretion.

The data show that APVO436 and the Aptevo-generated version of MDG006 are both effective at stimulating a tumor-directed immune response by inducing comparable T-cell activation, proliferation and cytotoxicity.  However, in these preclinical studies, APVO436 induced lower levels of several T-cell cytokines, including IFNγ, IL-2, IL-6, TNFα and several additional cytokines, suggesting a potential safety advantage with APVO436.

“We are especially excited about these latest data for APVO436, which continue to show robust T-cell engagement and cytotoxic activity with reduced levels of cytokine release.  Importantly, IFNγ, IL-6, and TNFα are considered to be the most relevant cytokines responsible for dosing toxicities observed in clinical studies with T-cell engaging molecules, which suggests that APVO436 could offer the potential for reduced toxicities compared to other CD123 x CD3 T-cell engagers at comparable or higher doses,” said Jane Gross, Ph.D., Senior Vice President and Chief Scientific Officer for Aptevo.

“The accumulating data for APVO436 showing enhanced stability, extended half-life in rodents of up to 12.5 days, desirable manufacturing characteristics, and reduced cytokine release in preclinical studies, support our assessment of APVO436 as a “Best-in-Class” anti-CD123 x anti CD3 immunotherapeutic.  We plan to file an IND for APVO436 in the upcoming weeks and commence a Phase 1 clinical trial of APVO436 later this year in acute myeloid leukemia and myelodysplastic syndrome,” noted Dr. Gross.

Acute myeloid leukemia (AML) is a form of blood and bone marrow cancer that is characterized by rapid disease progression.  While treatments for AML are available, there remains a high unmet medical need for targeted therapies addressing patients with relapsed and refractory disease, and patients who cannot tolerate traditional chemotherapy.  The American Cancer Society estimates that approximately 20,000 new cases of AML are diagnosed each year in the United States. 

Myelodysplastic syndromes (MDS) are conditions associated with abnormalities in the blood-forming cells in the bone marrow.  Approximately 1 in 3 patients with MDS will progress to have AML.  The American Cancer Society estimates that approximately 10,000 new cases of MDS are diagnosed each year in the United States.

In a poster session on Monday, April 16, 2018, Aptevo scientists presented comprehensive data from a series of preclinical studies of APVO436 showing it is a potent inducer of redirected T-cell killing of AML tumor cells both and through the dual targeting of CD123 (a cell surface receptor highly expressed in several hematological malignancies) and CD3 (a T-cell co-receptor that promotes cytotoxicity.) 

The data presented show that APVO436:

APVO436 is an optimized, next generation bispecific antibody candidate designed to simultaneously target CD123 and CD3 and redirect T-cell cytotoxicity to the tumor.  APVO436 was built on Aptevo’s proprietary ADAPTIR protein therapeutic platform.  Focused on generating novel, targeted bispecific antibody-based immunotherapies for cancer and autoimmune diseases, the ADAPTIR platform offers key advantages over other bispecific formats, derived in part from the flexible and modular nature of the ADAPTIR structure. These advantages include: (i) achieving potent biological activity and extended half-life while retaining desirable manufacturing characteristics; (ii) unique properties for redirecting T-cell cytotoxicity (RTCC) compared to other bispecific platforms, including a favorable cytokine release profile; (iii) ability to achieve target-dependent induction of RTCC at lower concentrations than other bispecific antibody formats; and (iv) flexibility to build ADAPTIR candidates with diverse mechanisms of action, including RTCC, and targeted cytokine release and others. Two ADAPTIR molecules are currently in clinical development, with several more ADAPTIR bispecific immunotherapies in preclinical development.

There are a number of important factors that could cause Aptevo’s actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo’s business or prospects; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as filed on March 13, 2018 and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo’s expectations in any forward-looking statement.

 

More news and information about Aptevo Therapeutics Inc.

Published By:

Globe Newswire: 14:02 GMT Monday 16th April 2018

Published: .

Search for other references to "aptevo" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers